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n the United States and most other developed
countries, lung cancer is the leading cause of
cancer-related death. Notoriously hard to detect in
its early stages, the overall five-year survival rate for
the disease is only 14 percent.
Maik Hüttemann, Ph.D., assistant professor of
molecular medicine and genetics in Wayne State
University’s School of Medicine, along with research
associate Jeffrey Doan, Ph.D., is working to improve
those odds by developing a screening technique for
a gene that may be indicative of lung cancer. He
is developing a platform technology which utilizes
probe ligation and rolling circle amplification to
screen for any target gene in many different types
of diseases.
To begin, though, the research has centered on
cytochrome c oxidase (or COX), the “pacemaker
of aerobic metabolism.” The level of COX4-2, a
lung-specific COX gene, directly correlates with
the amount of oxygen in lung tissue. “And oxygen
levels,” Hüttemann said, “can indicate whether
tissue is healthy or cancerous.”
“In 70 percent of all human diseases, we find a
change in the oxygen environment,” Hüttemann
said. “COX4-2 levels may be one of the early
indicators of that shift in lung cancer tissue.”
In healthy cells, the primary type of metabolism
is aerobic oxidative phosphorylation in the
mitochondria. This type of metabolism produces
adenosine triphosphate (ATP), biological energy that
fuels most of the body’s processes. In cancer cells,
however, the predominant type of metabolism is
glycolysis, an anaerobic process. Rather than energy,
products of glycolysis and associated pathways are
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“In 70 percent of all human
diseases, we find a change in
the oxygen environment, COX4-2
levels may be one of the early
indicators of that shift in lung
cancer tissue.”
— Dr. Hüttemann

required for the proliferating cell. “The switch from
aerobic to glycolytic metabolism reflects the cancer
cell’s need for building blocks for DNA, lipid, and
protein biosynthesis,” Hüttemann said.
In an ongoing study, Hüttemann and colleagues
found that COX4-2 is dramatically downregulated
in lung cancer. This was measured against the
somatic form of the gene, COX4-1, which is
expressed at similar levels in cancer and non-cancer
tissue. The finding holds for various types of lung
cancer and lung cancer cell lines – approximately
80 were tested – including a cell culture model
simulating carcinogenesis in vivo. “In that model,
COX4-2 is downregulated from the earliest stages,”
he said. “And, this makes sense because we have
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shown that COX4-2 makes cells more aerobic,
which is the opposite of what the cancer wants.
Therefore, our results suggest that the COX4-2 gene
is a mechanism-based marker for lung cancer.”
Hüttemann’s current work aims to expand on
these findings by investigating expression levels
of COX4-2 with greater accuracy. He is developing
probe ligation and rolling circle amplification
techniques to detect levels of both COX4-1 and
COX4-2. “Differences between the levels of these
two genes may indicate the presence of cancer.”
The techniques entail Hüttemann’s lab
synthesizing DNA segments, or “probes,” that
recognize and attach to the target gene. Using DNA
polymerase and a circular DNA template, DNA
generation amplifies the target of the gene-specific
probes 1000-fold.
“Using the DNA extensions, the signals of the
two genes are ‘amplified,’ enabling our lab to locate
and quantify the levels of COX4-1 and COX4-2 with
much greater accuracy than we ever could before,”
Hüttemann said.
Hüttemann’s group is currently working to
further develop the techniques into a robust
working assay in the lab. Once this is achieved, the
next step will be to test it using clinical specimens
from lung cancer patients.
Improved ability to measure the levels of the
COX genes may result in a test for the early
screening of lung cancer. “Only 15 percent of lung
cancer tumors are detected in time to do something
about it,” Hüttemann said. “Our hope with this
assay is to develop a robust screening method. In
particular, individuals at high risk for developing
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About Dr. Maik Hüttemann:
Dr. Hüttemann received a B.S. and
an M.S. in chemistry, and a Ph.D. in
biochemistry and molecular biology
from the University of Marburg in
Germany. He joined Wayne State
University in 2000.

Maik Hüttemann and his research team are
developing a platform technology to screen
for target genes in lung cancer and other
diseases.
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lung cancer, including smokers would benefit from
such a test.”
Although lung cancer is Hüttemann’s primary
interest, he also aims to develop the assay as a
platform technology to screen for any gene.
“Although this step is further into the future,
if we can successfully develop the technology to
detect a gene of interest and amplify its signal, our
ability to screen for specific genes may increase
dramatically,” Hüttemann said. “This, in turn, may
help in the early detection of not only different
kinds of cancers, but perhaps other diseases such
as neurodegenerative disorders, diabetes and
innumerable other health problems with a genetic
footprint.”
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To learn more, visit:
http://genetics.wayne.edu/faculty/huttemann/index.php

http://digitalcommons.wayne.edu/newscience/vol19/iss1/16

2

